A Case Report of Primary Pericardial Malignant Mesothelioma Treated with Pemetrexed and Cisplatin.
10.3346/jkms.2017.32.11.1879
- Author:
Jung Sun KIM
1
;
Sang Yup LIM
;
Jinwook HWANG
;
Eun Joo KANG
;
Yoon Ji CHOI
Author Information
1. Division of Hematology/Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. yoonji23@hanmail.net
- Publication Type:Case Report
- Keywords:
Primary Pericardial Mesothelioma;
Cardiac Tamponade;
Pemetrexed;
Cisplatin
- MeSH:
Aged;
Asbestos;
Cardiac Tamponade;
Cisplatin*;
Disease Progression;
Drug Therapy;
Female;
Humans;
Incidence;
Mesothelioma*;
Pemetrexed*;
Pericardial Effusion;
Prognosis;
Treatment Outcome
- From:Journal of Korean Medical Science
2017;32(11):1879-1884
- CountryRepublic of Korea
- Language:English
-
Abstract:
Primary pericardial malignant mesothelioma (PPM) is a very rare malignancy, with an incidence of less than 0.002% and represents less than 5% of all mesotheliomas. The cause of pericardial mesothelioma is uncertain that differ from pleural mesothelioma which is associated with asbestos exposure. This malignancy is terribly aggressive and has very poor prognosis with less than six months of overall survival. We present a case of a 71-year-old woman who was diagnosed with cardiac tamponade caused by PPM and received chemotherapy with pemetrexed and cisplatin for six months. During two years she was alive without disease progression. To better understand the clinical, pathologic features and treatment outcome of this entity, we reviewed 23 cases described in the English literature from 2009, together with our case, provided a total of 24 cases. Based on this review, we suggest that PPM must be considered in patients who have unexplained massive pericardial effusion and recommend chemotherapy with pemetrexed and cisplatin for the better outcome of PPM.
